A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1999 May 29

PMID 10348748

Citations 73

Authors

I K Srivastava

A B Vaidya

Affiliations

Soon will be listed here.

Abstract

A combination of atovaquone and proguanil has been found to be quite effective in treating malaria, with little evidence of the emergence of resistance when atovaquone was used as a single agent. We have examined possible mechanisms for the synergy between these two drugs. While proguanil by itself had no effect on electron transport or mitochondrial membrane potential (DeltaPsim), it significantly enhanced the ability of atovaquone to collapse DeltaPsim when used in combination. This enhancement was observed at pharmacologically achievable doses. Proguanil acted as a biguanide rather than as its metabolite cycloguanil (a parasite dihydrofolate reductase [DHFR] inhibitor) to enhance the atovaquone effect; another DHFR inhibitor, pyrimethamine, also had no enhancing effect. Proguanil-mediated enhancement was specific for atovaquone, since the effects of other mitochondrial electron transport inhibitors, such as myxothiazole and antimycin, were not altered by inclusion of proguanil. Surprisingly, proguanil did not enhance the ability of atovaquone to inhibit mitochondrial electron transport in malaria parasites. These results suggest that proguanil in its prodrug form acts in synergy with atovaquone by lowering the effective concentration at which atovaquone collapses DeltaPsim in malaria parasites. This could explain the paradoxical success of the atovaquone-proguanil combination even in regions where proguanil alone is ineffective due to resistance. The results also suggest that the atovaquone-proguanil combination may act as a site-specific uncoupler of parasite mitochondria in a selective manner.

Citing Articles

Treatment of avian malaria in captive African penguins () by the combination of atovaquone and proguanil hydrochloride.

Samarelli R, Pugliese N, Saleh M, Prioletti M, Cordon R, Cavicchio P Int J Vet Sci Med. 2025; 13(1):1-8.

PMID: 40007641 PMC: 11852231. DOI: 10.1080/23144599.2025.2460919.

Effect of SLC22A1 polymorphism on the pharmacokinetics of proguanil in Korean: A semi-physiologic population pharmacokinetic approach.

Khwarg J, Yang E, Park C, Ji S, Yu K, Lee S Clin Transl Sci. 2024; 17(12):e70103.

PMID: 39668580 PMC: 11638344. DOI: 10.1111/cts.70103.

A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants.

Kuemmerle A, Gossen D, Marx M, Lorch U, Szramowska M, Kumar A Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9823-9832.

PMID: 38918235 PMC: 11582152. DOI: 10.1007/s00210-024-03245-x.

Tafenoquine for Relapsing Babesiosis: A Case Series.

Krause P, Rogers R, Shah M, Kang H, Parsonnet J, Kodama R Clin Infect Dis. 2024; 79(1):130-137.

PMID: 38814096 PMC: 11259219. DOI: 10.1093/cid/ciae238.

Omega-3 and omega-6 polyunsaturated fatty acids and their potential therapeutic role in protozoan infections.

Rahman S, Weng T, Qadeer A, Nawaz S, Ullah H, Chen C Front Immunol. 2024; 15:1339470.

PMID: 38633251 PMC: 11022163. DOI: 10.3389/fimmu.2024.1339470.

References

Radloff P, Philipps J, Nkeyi M, Hutchinson D, Kremsner P . Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet. 1996; 347(9014):1511-4. DOI: 10.1016/s0140-6736(96)90671-6. View

Gutteridge W, Dave D, Richards W . Conversion of dihydroorotate to orotate in parasitic protozoa. Biochim Biophys Acta. 1979; 582(3):390-401. DOI: 10.1016/0304-4165(79)90131-4. View

Srivastava I, Rottenberg H, Vaidya A . Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997; 272(7):3961-6. DOI: 10.1074/jbc.272.7.3961. View

Helsby N, Edwards G, Breckenridge A, Ward S . The multiple dose pharmacokinetics of proguanil. Br J Clin Pharmacol. 1993; 35(6):653-6. PMC: 1381611. DOI: 10.1111/j.1365-2125.1993.tb04197.x. View

Chance B, Williams G . A simple and rapid assay of oxidative phosphorylation. Nature. 1955; 175(4469):1120-1. DOI: 10.1038/1751120a0. View

Birkett D, Rees D, Andersson T, Gonzalez F, Miners J, Veronese M . In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol. 1994; 37(5):413-20. PMC: 1364895. DOI: 10.1111/j.1365-2125.1994.tb05707.x. View

Hammond D, Burchell J, Pudney M . Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol. 1985; 14(1):97-109. DOI: 10.1016/0166-6851(85)90109-4. View

Dunn C, Peters D . Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs. 1995; 49(5):721-49. DOI: 10.2165/00003495-199549050-00007. View

Looareesuwan S, Viravan C, Webster H, Kyle D, Hutchinson D, Canfield C . Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg. 1996; 54(1):62-6. DOI: 10.4269/ajtmh.1996.54.62. View

10.

Schafer G . Site-specific uncoupling and inhibition of oxidative phosphorylation by biguanides. II. Biochim Biophys Acta. 1969; 172(2):334-7. DOI: 10.1016/0005-2728(69)90077-2. View

11.

CARRINGTON H, CROWTHER A, DAVEY D, LEVI A, ROSE F . A metabolite of paludrine with high antimalarial activity. Nature. 1951; 168(4288):1080. DOI: 10.1038/1681080a0. View

12.

Helsby N, Ward S, Edwards G, Howells R, Breckenridge A . The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol. 1990; 30(4):593-8. PMC: 1368250. DOI: 10.1111/j.1365-2125.1990.tb03818.x. View

13.

Peters W . Plasmodium: resistance to antimalarial drugs. Ann Parasitol Hum Comp. 1990; 65 Suppl 1:103-6. DOI: 10.1051/parasite/1990651103. View

14.

Araujo F, Huskinson J, Remington J . Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother. 1991; 35(2):293-9. PMC: 244994. DOI: 10.1128/AAC.35.2.293. View

15.

Ward S, Helsby N, Skjelbo E, Brosen K, Gram L, Breckenridge A . The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol. 1991; 31(6):689-92. PMC: 1368581. DOI: 10.1111/j.1365-2125.1991.tb05594.x. View

16.

Canfield C, Pudney M, Gutteridge W . Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol. 1995; 80(3):373-81. DOI: 10.1006/expr.1995.1049. View

17.

WENDEL W . The influence of napthoquinones upon the respiratory and carbohydrate metabolism of malarial parasites. Fed Proc. 2010; 5:406. View

18.

Fidock D, Wellems T . Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997; 94(20):10931-6. PMC: 23535. DOI: 10.1073/pnas.94.20.10931. View

19.

Kovacs J . Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet. 1992; 340(8820):637-8. DOI: 10.1016/0140-6736(92)92172-c. View

20.

Hughes W, Gray V, Gutteridge W, Latter V, Pudney M . Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1990; 34(2):225-8. PMC: 171561. DOI: 10.1128/AAC.34.2.225. View